Zobrazit minimální záznam

dc.contributor.authorFait, Tomas
dc.contributor.authorBaltazár, Tivadar
dc.contributor.authorBubenickova, Leona
dc.contributor.authorKestranek, Jan
dc.contributor.authorStepan, Martin
dc.contributor.authorMuller, Miroslav
dc.contributor.authorTurcan, Pavel
dc.date.accessioned2025-04-09T00:03:20Z
dc.date.available2025-04-09T00:03:20Z
dc.date.issued2023
dc.identifier.issn2077-0383 Sherpa/RoMEO, JCR
dc.identifier.urihttps://repozitar.mendelu.cz/xmlui/handle/20.500.12698/2051
dc.description.abstractIntroduction: Vaginal laxity is a widespread and undertreated medical condition associated especially with vaginal parity. Aim: To evaluate the efficacy and safety of electroporation therapy treatment of vulvovaginal laxity by the Jett Plasma for Her II device. Methods: The Jett Plasma for Her II Study is a multicentric, prospective, randomized, single-blinded, and controlled study. Women presenting with vaginal laxity were randomized to receive electroporation therapy delivered to the vaginal tissue (active-82 patients) vs. therapy with zero intensity (placebo-9 patients). Results: A total of 91 subjects whose average age was 48.69 +- 10.89 were included. Due to the results of a one-way analysis of variance, it may be concluded that in the case of the vaginal laxity questionnaire (VLQ), there is a statistically significant difference between actively treated patients and the placebo group (F1,574 = 46.91; p < 0.001). In the case of the female sexual function index (FSFI), a one-way ANOVA test also showed a statistically significant difference between the actively treated patients and the placebo group (F1,278 = 7.97; p = 0.005). In the case of the incontinence impact questionnaire-7 (IIQ-7), a one-way ANOVA test showed a statistically significant difference between the actively treated patients and the placebo group (F1,384 = 15.51; p < 0.001). It confirms that improvement of vaginal laxity is conjoined with benefits in symptoms of urinary incontinence. Biopsy performed after the end of the treatment shows an increase in the vaginal mucosa thickness by an average of 100.04% in the active group. The treatment was well tolerated with no adverse events. No topical anesthetics were required. Conclusions: Treatments of vulvovaginal laxity by electroporation therapy achieved significant and sustainable 12-month effectiveness. Responses to the questionnaires also suggest subjective improvement in self-reported sexual function, incontinence, sexual satisfaction, and urogenital distress.en
dc.format6234
dc.publisherMDPI AG (Multidisciplinary Digital Publishing Institute-MDPI)
dc.relation.ispartofJournal of Clinical Medicine
dc.relation.urihttps://doi.org/10.3390/jcm12196234
dc.rightsCC BY 4.0
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectvaginal laxityen
dc.subjectvulvovaginal laxityen
dc.subjectnonsurgical vaginal tighteningen
dc.subjectincontinenceen
dc.subjectsexual functionen
dc.subjecturogenital distressen
dc.subjectelectroporation therapyen
dc.titleTreatment of Vulvovaginal Laxity by Electroporation: The Jett Plasma Medical for Her II Studyen
dc.typeJ_ČLÁNEK
dc.date.updated2025-04-09T00:03:20Z
dc.description.versionOA
local.identifier.doi10.3390/jcm12196234
local.identifier.scopus2-s2.0-85173822593
local.identifier.wos001085248800001
local.number19
local.volume12
local.identifier.obd43925487
local.identifier.e-issn2077-0383
dc.identifier.orcidBaltazár, Tivadar 0000-0001-5381-257X
local.contributor.affiliationAF


Soubory tohoto záznamu

Thumbnail

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam

CC BY 4.0
Kromě případů, kde je uvedeno jinak, licence tohoto záznamu je CC BY 4.0